Choosing the Right Specialist for Advanced Eyelid and Oculoplastic Procedures 

Medical News Bulletin - Daily Medical News, Health News, Clinical Trials And Clinical Research, Medical Technology, Fitness And Nutrition News–In One Place

Eyelid surgery has become popular among individuals that would like to make themselves look better or fix their functional problems. However, when sensitive eyelid and oculoplastic surgery are concerned, the appropriate expert is the cosmetic one, yet, above all, it is a question of safety, experience, and something natural that results in you looking like […]

The post Choosing the Right Specialist for Advanced Eyelid and Oculoplastic Procedures  appeared first on Medical News Bulletin.

Eye care practitioners urge FDA to approve low-dose atropine

A Change.org petition with more than 800 signatures is calling on the FDA to approve low-dose atropine to slow the progression of pediatric myopia.
It comes after the FDA decided not to approve SYD-101 (0.01% atropine, Sydnexis) in October despite acknowledging the drug met its primary efficacy endpoint in a phase 3 study and had no safety or quality issues.
The petition was posted on Dec. 9 by the Pediatric Progressive Myopia Coalition, a partnership between Robert S. Gold, MD, FAAP, a pediatric ophthalmologist at Eye Physicians of Central Florida, and Cheryl Chapman, OD, FIAOMC, FAAO, Dipl

Q&A: Key telehealth provisions in jeopardy as lawmakers debate spending package

The American Telemedicine Association, or ATA, urged Congress to quickly act to avoid the expiration of key telehealth services on Jan. 30, which are being threatened by an “unrelated partisan debate.”
According to an ATA press release, among the provisions set to expire include the Medicare telehealth waivers and Acute Hospital Care at Home program.
These provisions previously lapsed on Oct. 1 of last year but were temporarily extended on Nov. 13.
ATA Vice President of Public Affairs Alexis Apple told Healio that multiyear extensions for these services, “as well as some other telehealth

Wearable device shows promise for restoring speech in dysarthria

A wearable silent speech processing system showed promise for restoring fluency and expression for individuals with speech problems resulting from stroke, according to data published in Nature Communications.
“The unmet needs we try to serve with our device originate from a gap that exists in a large number of people who experience dysarthria, a speech impairment where they know exactly what they want to say but physically can’t say it clearly,” Luigi G. Occhipinti, CEng, PhD, research professor of smart electronics, biosystems and AI at the University of Cambridge in the United Kingdom, told

IL-6 inhibition promising as pathway for retinal disease therapy

WAIKOLOA, Hawaii — In this Healio Video Perspective from Retina 2026, Ehsan Rahimy, MD, discusses the potential of IL-6 inhibition for the treatment of exudative retinal diseases.
Rahimy said that even with the success of anti-VEGF therapies, many patients with age-related macular degeneration and diabetic macular edema are incomplete or suboptimal responders.
{{VIDEO}}
“That begs the question that other potential pathways may be involved in these disease processes,” he said. “IL-6 is a very important and potent inflammatory marker, which potentiates the activities of VEGF leading to vascular

Clinicians unite behind AAP vaccine schedule

The American Academy of Pediatrics’ childhood immunization schedule for 2026 preserves recommendations for vaccines that are no longer universally recommended under HHS’s overhaul of the CDC schedule.
The AAP releases an updated vaccine schedule every year, but this is the first time in many years that it has split from the CDC schedule.
“We used to partner very closely with CDC to create a unified or harmonized set of vaccine recommendations, but recent changes are a strong departure from medical evidence and no longer offer the optimal way to prevent illness in children,” Sean T. O’Leary, MD,

US obesity prevalence projected to rise to nearly 47% by 2035

The prevalence of obesity in the United States is projected to increase to 126 million by 2035, according to a new study published in JAMA.
“Obesity continues to increase, especially in young people, and remains a major public health threat,” Catherine O. Johnson, PhD, MPH, a scientist at the Institute for Health Metrics and Evaluation, University of Washington, Seattle, told Healio. “One of our major findings was the large increases in the prevalence of obesity in younger age groups for all race and ethnicity groups, highlighting the need for effective strategies to prevent weight gain and

Recreational drug use linked to poor outcomes after heart attack

Testing positive for recreational drugs at the time of admission with acute coronary syndrome was associated with increased risk for major adverse cardiovascular events in the following year, researchers reported.
The link between recreational drug use and MACE after hospitalization for ACS was only significant in patients who experienced STEMI, a subgroup that may benefit from target interventions, according to the study.
A new analysis of the ADDICT-ICCU study was published in JACC: Advances.
“While traditional risk factors such as hypertension, diabetes and dyslipidemia are well-established,

Proteinuria remission with sparsentan supports kidney function

Patients with immunoglobin A nephropathy who reached complete remission of proteinuria with sparsentan had greater eGFR preservation and fewer kidney failure events compared with those who did not reach complete remission, data show.
The data were published in the Clinical Journal of the American Society of Nephrology.
Sparsentan (Filspari, Travere Therapeutics), a dual-endothelin angiotensin II receptor antagonist, demonstrated greater efficacy in reducing proteinuria and preserving kidney function vs. maximum-dose irbesartan for adults with immunoglobulin A nephropathy (IgAN) in the phase 3

What to know about America’s newly proposed sunscreen ingredient

After years of advocacy for modernization and legislative efforts, the FDA formally proposed adding bemotrizinol to the list of active sunscreen ingredients in the U.S.
On Dec. 11, 2025, the agency announced that it is considering a request from the ingredient’s developers, dsm-firmenich, to include bemotrizinol in the over-the-counter sunscreen monograph. If approved, it would become the first new sunscreen agent available in the U.S. since 1999.
Recent U.S. legislative reforms have allowed the FDA to process applications for new sunscreen ingredients, which have been held up for decades in